10月9日上午，北京市委书记尹力会见瑞士罗氏集团董事会主席施万。尹力说，罗氏集团是全球领先的 生物制药和诊断企业，北京愿与罗氏集团共同把握机遇，深化互利合作，实现共赢发展。希望罗氏集团 加强在京投资和业务布局，深化与医院、科研院所、医药企业等产学研合作，在肿瘤、免疫、神经退行 性疾病等领域推出更多创新药品和先进疗法，强化与北京科技企业跨界合作，在人工智能辅助药物开 发、智能检测诊断、数字化健康管理等方面形成更多示范应用，共同推进数字医疗发展。北京将在市场 准入、知识产权保护等方面提供便利，为广大在京企业营造更加优良的发展环境。施万表示，中国医药 健康市场规模巨大，罗氏集团愿持续扎根中国，实现更大发展。北京发展医药健康产业优势突出，罗氏 集团将扩大在京投资和业务布局，与北京科研、医疗机构等深化联合创新，共促数字医疗发展，引入更 多高质量药物及诊断产品，不断增进人民群众健康福祉。（北京日报） ...

周三，美国远程医疗公司Teladoc Health(TDOC.US)股价走高，截至发稿，该股涨超9.7%，报9.185美 元。消息面上，上周知名做空机构Citron Research罕见发表看多评论，称他们"并非看错，只是看早"， 重申对该公司长期潜力的信心。Teladoc近年来在数字医疗与虚拟诊疗领域深耕，尽管股价自新冠疫情 高点回落，机构分析人士指出，随着医疗保险和企业健康计划的数字化转型加速，该公司有望迎来新的 增长契机。 ...

智通财经APP获悉，周三，美国远程医疗公司Teladoc Health(TDOC.US)股价走高，截至发稿，该股涨超 9.7%，报9.185美元。消息面上，上周知名做空机构Citron Research罕见发表看多评论，称他们"并非看 错，只是看早"，重申对该公司长期潜力的信心。Teladoc近年来在数字医疗与虚拟诊疗领域深耕，尽管 股价自新冠疫情高点回落，机构分析人士指出，随着医疗保险和企业健康计划的数字化转型加速，该公 司有望迎来新的增长契机。 ...

健康160(02656)再涨超10%，高见39.5港元，较招股价11.89港元已涨超230%。截至发稿，涨9.52%，报 39.1港元，成交额2099.57万港元。 招股书显示，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。此外，该公司亦通过在线医疗健康 服务平台-健康160平台提供数字医疗健康解决方案，赋能整个医疗健康产业链上的各平台参与方。截至 2025年3月31日，健康160的平台自成立以来已累计连接超过44,600家医疗健康机构。 ...

据悉，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。公司为客户 提供各种医药健康用品，以及全面的数字医疗健康解决方案。此外，该公司亦通过在线医疗健康服务平 台-健康160平台提供数字医疗健康解决方案，赋能整个医疗健康产业链上的各平台参与方。截至2025年 3月31日，健康160的平台自成立以来已累计连接超过44,600家医疗健康机构，其中包括超过14,400家医 院(包括3,430家三级医院)及超过30,200家基层医疗卫生机构。 健康160(02656)尾盘涨超10%，高见35港元创上市新高，较招股价11.89港元已涨近两倍。截至发稿，涨 10.16%，报34.92港元，成交额3579.08万港元。 ...

Core Insights - Digital healthcare is rapidly integrating into daily life, showcasing advanced technologies and interactive experiences at the Global Digital Trade Expo [1] Group 1: Digital Healthcare Innovations - The fourth-generation flexible exoskeleton robot developed in China outperforms similar products in endurance and adaptability, marking a significant advancement in rehabilitation equipment [2] - The brain-controlled exoskeleton allows patients to control a mechanical arm using muscle signals, achieving a response time of less than 200 milliseconds, demonstrating international leadership in technology [2] - The fully automated, unmanned cell experiment assembly line by Deshi Bio is a groundbreaking system that automates traditional laboratory processes, enhancing efficiency and accuracy [3] Group 2: AI and Traditional Medicine - An AI medical assistant translates complex health reports into understandable language within three seconds, currently utilized in over 500 medical institutions, interpreting more than 200,000 reports daily [4] - The AI-based traditional Chinese medicine consultation experience combines tongue image scanning and pulse diagnosis to generate health reports in 30 seconds, revitalizing traditional practices with technology [4] - Smart elderly care devices, including companion robots and monitoring systems, significantly reduce caregiver workload and enhance emotional support for the elderly [4] Group 3: Exhibition Highlights - The digital healthcare exhibition features major international companies like Medtronic and GE Healthcare, alongside innovative local enterprises, showcasing cutting-edge medical technology and intelligent health services [4] - Attendees can engage in immersive experiences with AI-assisted diagnostics and remote surgeries, enhancing their understanding of future healthcare environments [5] - The expo will host ten professional forums featuring industry experts and academicians discussing the latest trends in digital healthcare, providing valuable insights to participants [6]

中新网杭州9月23日电(张煜欢)第四届全球数字贸易博览会(下称"数贸会")将于9月25至29日在浙江杭州 举办。作为中国数字贸易领域唯一一个国家级、国际性、专业型展会，本届数贸会打造1个主题展馆和7 个特色展区，涵盖智能机器人、时空智能、人工智能、数字医疗等前沿领域，邀请超千家国际知名头部 企业、超万名国际专业观众及客商参展参会，共商合作、共促发展、共享成果。 在数字化层面，对接会涉及对多个临床场景数字化应用的专题讨论，将围绕"数字筛查—智能诊断—精 准治疗—全周期管理"的闭环落地场景，进一步挖掘数据要素在医疗全链条中的乘数效应。 届时大会将集聚政策职能部门、头部企业及资本等产业生态资源，探索生命健康产业的新科技、新业 态、新模式，打造生命大健康产业的投融资服务平台、技术对接合作平台、行业趋势发布平台、高端人 才集聚平台；深化临床科研、数字医疗健康解决方案、产业与资本融合与发展；创新医疗生态圈建设、 共享数贸发展机遇，助推高水平打造生命健康产业高地。 具体来看，第四届数贸会的数字医疗板块将延续"三个一"模式，即举办一场高端产业对接会、扩容一批 专业委员会成员单位、设立一个数字医疗专题展区，系统化推动创新链、产 ...

Core Viewpoint - The Federal Reserve's interest rate cut has led to a sector rotation towards healthcare and financial stocks, with Hims & Hers Health Inc. positioned at the intersection of healthcare and technology, attracting mixed opinions from investors [1][2]. Company Performance - Hims & Hers Health reported Q2 2025 earnings of $544.8 million, marking a 73% increase year-over-year. The company also achieved a net subscriber count of 2.4 million, a 31% increase from the previous year [5]. - Average revenue per user rose from $57 in 2024 to $74 in 2025, reflecting a 30% increase, indicating improved customer retention and spending [5]. Valuation Metrics - Hims & Hers trades at a price-to-book (P/B) ratio of 25.9x, significantly higher than the medical sector average of 13.6x, suggesting that the market perceives its growth as both real and sustainable [6]. - The consensus price target for Hims & Hers is $38.92, indicating a potential downside of about 33% from recent prices, reflecting a cautious sentiment among analysts [8]. Analyst Sentiment - Maria Ripps of Canaccord Genuity has reiterated a Buy rating with a price target of $68, suggesting a potential upside of 17% from current levels, driven by strong earnings and optimism regarding lower interest rates [9]. - The stock has seen a recent surge of 32.9%, attributed to strong earnings and investor confidence in future growth opportunities [9]. Market Positioning - Hims & Hers is positioned in a favorable market environment characterized by recurring revenue, a growing customer base, and increasing per-user spending, which enhances its scalability [10]. - The company's strong fundamentals and market momentum support its valuation, moving it beyond a speculative investment [12].

东京, Sept. 20, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) 宣布参加将于 2025 年 9 月 24 日举行的 C3 Davos of Healthcare™ 日本峰会，此次峰会以“三国合作：跨越国界在医疗保健领域架起桥梁”为主题，汇聚全球领导者、政策制定者、投资者和创新者，促进国际对话与合作。 沙特王室顾问、KFSHRC 首席执行官 Majid Alfayyadh 博士阁下将作为 KFSHRC 代表团的核心成员，发表题为“KFSHRC 对综合医疗保健和投资于现代医学新基础设施的愿景”的主旨演讲。 在演讲中，Alfayyadh 博士将介绍沙特构建互联互通且以患者为中心的医疗保健生态系统的战略，重点阐述该国在数字医疗、医院扩建以及医学教育方面的举措。 他还将阐述公私合伙、外国投资和监管改革是如何正在塑造沙特医疗保健领域的未来，就沙特的宏伟计划以及全球合作机遇发表见解。 作为流程的一部分，KFSHRC 的思想领袖们将进行有关医疗保健转型的战略讨论。 KFSHRC 首席教育与培 ...

Core Viewpoint - The Jinan Precision Medicine Industrial Park is rapidly developing as a key component of the Jinan International Medical Center, providing essential infrastructure and comprehensive services to help resident companies overcome development bottlenecks and achieve rapid transformation of technological achievements [1][2]. Group 1: Company Development - Jinan Huayin Kang Medical Testing Co., Ltd. focuses on third-party medical diagnostic services and has initiated a remote pathology platform project to convert traditional glass pathology slices into digital images, enabling remote diagnosis for grassroots hospitals [1][2]. - Shandong Aopeng Intelligent Technology Co., Ltd. has achieved a significant breakthrough with its self-developed intelligent robot successfully completing an all-automated interventional surgery animal experiment, demonstrating sub-millimeter operational precision [2][3]. Group 2: Market Opportunities and Challenges - The Precision Medicine Industrial Park has facilitated the development of resident companies by coordinating support and policy assistance, leading to a 10% increase in the budget for Jinan Huayin Kang this year compared to last year [2]. - The park has organized product promotion events and established communication channels with clinical experts, which are crucial for accelerating product iteration and market entry for companies like Aopeng Intelligent [3]. Group 3: Growth Metrics - The number of registered and resident companies in the Jinan Precision Medicine Industrial Park has increased by 248% and 300% respectively this year, indicating a significant improvement in both quantity and quality of enterprises [3]. - The park focuses on providing tailored services to different types of companies, including high-end medical services, new-generation biotechnology, high-end medical devices, and digital healthcare, covering nearly 20 sub-sectors [3][4]. Group 4: Strategic Development - The park is forming a comprehensive medical industry chain with upstream and downstream connections, focusing on new areas such as cell and gene therapy, brain-machine interfaces, and AI healthcare [4]. - By creating public technology platforms and integrating market resources, the park is enhancing its "precision" role and effectiveness, becoming a vital engine for the high-quality development of the Jinan International Medical Center [4].